Syndax Pharmaceuticals Inc [SNDX] stock is trading at $24.38, up 5.38%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SNDX shares have gain 8.48% over the last week, with a monthly amount glided 22.80%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 26, February 2024, Syndax Announces Participation at Two Upcoming Investor Conferences. In a post published today on Yahoo Finance, Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in the following sessions at two upcoming investor conferences:.
From an analyst’s perspective:
Syndax Pharmaceuticals Inc [NASDAQ: SNDX] stock has seen the most recent analyst activity on January 31, 2024, when Scotiabank downgraded its rating to a Sector Perform and also revised its price target to $23 from $36. Previously, Mizuho started tracking the stock with Buy rating on December 22, 2023, and set its price target to $45. On October 25, 2023, BofA Securities initiated with a Buy rating and assigned a price target of $29 on the stock. Goldman started tracking the stock assigning a Buy rating and suggested a price target of $30 on October 11, 2023. Scotiabank initiated its recommendation with a Sector Outperform. Guggenheim started tracking with a Buy rating for this stock on July 11, 2023, and assigned it a price target of $40.
Syndax Pharmaceuticals Inc [SNDX] stock has fluctuated between $11.22 and $25.75 over the past year. Currently, Wall Street analysts expect the stock to reach $37.67 within the next 12 months. Syndax Pharmaceuticals Inc [NASDAQ: SNDX] shares were valued at $24.38 at the most recent close of the market. An investor can expect a potential return of 54.51% based on the average SNDX price forecast.
Analyzing the SNDX fundamentals
Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.50 points at the first support level, and at 22.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.85, and for the 2nd resistance point, it is at 25.32.
Syndax Pharmaceuticals Inc [SNDX] reported earnings per share of -$0.73 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.79/share, meaning a difference of $0.06 and a surprise factor of 7.60%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.64 per share as compared to estimates of -$0.73 per share, a difference of $0.09 representing a surprise of 12.30%.
Ratios To Look Out For
For context, Syndax Pharmaceuticals Inc’s Current Ratio is 9.73. In addition, the Quick Ratio stands at 9.73 and the Cash Ratio stands at 0.05.
Transactions by insiders
Recent insider trading involved Morrison Briggs, Director, that happened on Aug 09 when 52855.0 shares were sold. Director, Meury William completed a deal on Aug 02 to sell 83000.0 shares. Meanwhile, Director Morrison Briggs sold 52855.0 shares on Jul 10.
